Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Biomaterials. 2014 Nov 15;39:39–46. doi: 10.1016/j.biomaterials.2014.10.061

Figure 2.

Figure 2

In vitro VEGFR targeting and serum stability studies. (A) Flow cytometry analysis of the GO nanoconjugates in HUVECs (VEGFR+) and 4T1 breast cancer cells (VEGFR-). (B) Serum stability study of 64Cu-GO-VEGF121 at 37 °C for 48 h.